Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by Atria Investments Inc

Atria Investments Inc lifted its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 70.6% in the fourth quarter, HoldingsChannel reports. The firm owned 22,684 shares of the biotechnology company’s stock after buying an additional 9,384 shares during the period. Atria Investments Inc’s holdings in Anavex Life Sciences were worth $244,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AVXL. Geode Capital Management LLC increased its stake in Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares during the last quarter. Nwam LLC increased its position in shares of Anavex Life Sciences by 0.3% during the 4th quarter. Nwam LLC now owns 913,051 shares of the biotechnology company’s stock worth $9,806,000 after purchasing an additional 2,575 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Anavex Life Sciences by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company’s stock worth $7,273,000 after purchasing an additional 11,239 shares during the last quarter. Barclays PLC raised its holdings in Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after buying an additional 64,101 shares during the period. Finally, Rhumbline Advisers lifted its position in Anavex Life Sciences by 2.9% in the fourth quarter. Rhumbline Advisers now owns 123,699 shares of the biotechnology company’s stock valued at $1,329,000 after buying an additional 3,498 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AVXL. D. Boral Capital reiterated a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, February 18th.

Anavex Life Sciences Price Performance

Shares of NASDAQ:AVXL opened at $9.31 on Wednesday. The firm’s 50-day moving average is $9.20 and its two-hundred day moving average is $8.09. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44. The firm has a market capitalization of $791.95 million, a PE ratio of -16.93 and a beta of 0.94.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. Analysts expect that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.